Altamira Therapeutics Ltd. (CYTO)

USD 0.3

(0.0%)

Market Cap (In USD)

1.13 Million

Revenue (In USD)

-

Net Income (In USD)

-7.27 Million

Avg. Volume

141.04 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.4-3.6
PE
0.1648
EPS
1.82
Beta Value
2.442
ISIN
BMG0360L1349
CUSIP
G0360L100
CIK
1601936
Shares
3778520.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Thomas Meyer Ph.D.
Employee Count
-
Website
https://altamiratherapeutics.com
Ipo Date
2014-08-06
Details
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.